148 related articles for article (PubMed ID: 35319100)
1. Sample size calculation for the augmented logrank test in randomized clinical trials.
Hattori S; Komukai S; Friede T
Stat Med; 2022 Jun; 41(14):2627-2644. PubMed ID: 35319100
[TBL] [Abstract][Full Text] [Related]
2. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
3. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
4. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
5. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
Cortés Martínez J; Geskus RB; Kim K; Melis GG
BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
[TBL] [Abstract][Full Text] [Related]
6. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
7. Combined test versus logrank/Cox test in 50 randomised trials.
Royston P; Choodari-Oskooei B; Parmar MKB; Rogers JK
Trials; 2019 Mar; 20(1):172. PubMed ID: 30885277
[TBL] [Abstract][Full Text] [Related]
8. Comparing sample size formulae for trials with unbalanced allocation using the logrank test.
Hsieh FY
Stat Med; 1992 Jun; 11(8):1091-8. PubMed ID: 1496196
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
10. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.
Tangen CM; Koch GG
J Biopharm Stat; 1999 May; 9(2):307-38. PubMed ID: 10379696
[TBL] [Abstract][Full Text] [Related]
11. Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata.
Lachin JM
Stat Med; 2013 Nov; 32(25):4413-25. PubMed ID: 23670965
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Phadnis MA; Wetmore JB; Mayo MS
Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
[TBL] [Abstract][Full Text] [Related]
13. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
Horiguchi M; Cronin AM; Takeuchi M; Uno H
Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
[TBL] [Abstract][Full Text] [Related]
14. An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials.
Garès V; Andrieu S; Dupuy JF; Savy N
Stat Med; 2015 Feb; 34(4):541-57. PubMed ID: 25388274
[TBL] [Abstract][Full Text] [Related]
15. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
Xu R; Mehrotra DV; Shaw PA
Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
[TBL] [Abstract][Full Text] [Related]
16. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations.
Karrison TG
Control Clin Trials; 1997 Apr; 18(2):151-67. PubMed ID: 9129859
[TBL] [Abstract][Full Text] [Related]
17. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
[TBL] [Abstract][Full Text] [Related]
18. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
19. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
Karrison T; Kocherginsky M
Clin Trials; 2018 Apr; 15(2):178-188. PubMed ID: 29502444
[TBL] [Abstract][Full Text] [Related]
20. Sample size determination in complex clinical trials comparing more than two groups for survival endpoints.
Ahnn S; Anderson SJ
Stat Med; 1998 Nov; 17(21):2525-34. PubMed ID: 9819843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
